Long-term Study Evaluating Joint Health in People With Haemophilia A Receiving Real-world Prophylactic Treatment With Efanesoctocog Alfa

StatusActive, Not Recruiting
PhasePhase 4
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Enrollment closed, study ongoing Show 5 more changesShow less
    • Enrollment target: estimated 250 to confirmed 252
    • Study sites: 29 to 31
    • Eligibility criteria expanded, about 12 words
    • Secondary endpoints: details revised at 6 of 27 entries
    • Study description revised
  2. Study sites: 27 to 29v7
  3. Study sites: 24 to 27v6
  4. Study sites: 21 to 24v5
  5. Study sites: 16 to 21v4
Show 2 earlier versionsHide 2 earlier versions
  1. Study sites: 7 to 16v3
  2. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 1 to 7
    • Start date changed from estimate of May 2025 to May 21, 2025
    v2
  1. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The rationale for this study is to further understand and describe the long-term prophylactic effectiveness of efanesoctocog alfa in preventing joint bleeds in a real-life setting.
Trial Details
NCT Number NCT06940830
Lead Sponsor Swedish Orphan Biovitrum
Collaborators: PSI CRO
Conditions
(from sponsor)		 Hemophilia A
Related terms Blood Coagulation Disorders, Coagulation Protein Disorders, Hemophilia A
Enrollment 252 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov